NASDAQ:ACLX

Arcellx Stock Insider Trading

Healthcare > Biotechnology

Buy ACLX

*Your capital is at risk

$115.07

+0 (+0%)

At Close: Jun 03, 2026

Arcellx Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -63.73. In total, the insiders bought 1.66M and sold 6.21M ACLX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-63.73
● Buy	1.66M shares
● Sell	6.21M shares
32% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Apr 28, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -63.73. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 28, 2026 Sell	Performance-based Restricted Stock Unit D-Return	Heery Christopher Chief Medical Officer	Officer	45 138 Value: $0
Apr 28, 2026 Buy	Performance-based Restricted Stock Unit A-Award	Elghandour Rami See Remarks	Officer	138 888 Value: $16.0M
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Elghandour Rami See Remarks	Officer	245 065 Value: $7.60M
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Elghandour Rami See Remarks	Officer	255 965 Value: $14.4M
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Elghandour Rami See Remarks	Officer	837 602 Value: $5.26M
Apr 28, 2026 Sell	Performance-based Restricted Stock Unit D-Return	Elghandour Rami See Remarks	Officer	138 888 Value: $0
Apr 28, 2026 Sell	Common Stock U-Tender	Elghandour Rami See Remarks	Officer	101 164 Value: $11.6M
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Elghandour Rami See Remarks	Officer	120 000 Value: $2.40M
Apr 16, 2026 Buy	Stock Option (right to buy) M-Exempt	Gilson Michelle Chief Financial Officer	C-Suite Officer	2 110 Value: $18.3K
Apr 16, 2026 Buy	Common Stock M-Exempt	Gilson Michelle Chief Financial Officer	C-Suite Officer	2 110 Value: $18.3K
Apr 15, 2026 Buy	Stock Option (right to buy) M-Exempt	Gilson Michelle Chief Financial Officer	C-Suite Officer	36 000 Value: $311.8K
Apr 15, 2026 Buy	Common Stock M-Exempt	Gilson Michelle Chief Financial Officer	C-Suite Officer	36 000 Value: $311.8K
Mar 17, 2026 Sell	Common Stock G-Gift	Gilson Michelle Chief Financial Officer	C-Suite Officer	5 000 Value: $0
Mar 04, 2026 Sell	Common Stock G-Gift	Elghandour Rami See Remarks	Officer	101 164 Value: $0
Feb 27, 2026 Sell	Common Stock S-Sale	Elghandour Rami See Remarks	Officer	89 916 Value: $10.2M
Feb 25, 2026 Sell	Common Stock S-Sale	Gilson Michelle Chief Financial Officer	C-Suite Officer	11 219 Value: $1.28M
Feb 19, 2026 Sell	Common Stock S-Sale	Gilson Michelle Chief Financial Officer	C-Suite Officer	100 Value: $7K
Feb 19, 2026 Sell	Common Stock S-Sale	Gilson Michelle Chief Financial Officer	C-Suite Officer	5 405 Value: $370.6K
Feb 19, 2026 Sell	Common Stock S-Sale	Gilson Michelle Chief Financial Officer	C-Suite Officer	2 879 Value: $195.0K
Feb 17, 2026 Sell	Common Stock S-Sale	Gilson Michelle Chief Financial Officer	C-Suite Officer	7 141 Value: $494.2K
Feb 17, 2026 Sell	Common Stock S-Sale	Gilson Michelle Chief Financial Officer	C-Suite Officer	4 150 Value: $290.6K
Feb 11, 2026 Sell	Common Stock G-Gift	Elghandour Rami See Remarks	Officer	198 000 Value: $0
Feb 11, 2026 Sell	Common Stock G-Gift	Elghandour Rami See Remarks	Officer	218 500 Value: $0
Jan 20, 2026 Sell	Common Stock S-Sale	Lubner David Charles Director	Director	6 000 Value: $450.0K
Jan 20, 2026 Buy	Common Stock M-Exempt	Lubner David Charles Director	Director	6 000 Value: $37.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ARCELLX, INC.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent Sp...

Read Full Profile Here